| scholarly article | Q13442814 |
| P2093 | author name string | J F Smyth | |
| S P Langdon | |||
| A Ritchie | |||
| K G Macleod | |||
| J M Sewell | |||
| P2860 | cites work | Characterization and properties of nine human ovarian adenocarcinoma cell lines. | Q52833986 |
| Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor | Q57424632 | ||
| Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor | Q59054268 | ||
| The pathway to signal achievement | Q59067952 | ||
| Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase | Q59566187 | ||
| Evidence for the involvement of transforming growth factor alpha and epidermal growth factor receptor autocrine growth mechanism in primary human ovarian cancers in vitro | Q67700822 | ||
| Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice | Q71574182 | ||
| United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition) | Q74155605 | ||
| The ErbB signaling network: receptor heterodimerization in development and cancer | Q29617919 | ||
| Receptors for epidermal growth factor and other polypeptide mitogens | Q34163558 | ||
| The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer | Q36135007 | ||
| Epidermal growth factor receptor-mediated cell motility: phospholipase C activity is required, but mitogen-activated protein kinase activity is not sufficient for induced cell movement | Q36234800 | ||
| Inhibition of transforming growth factor alpha (TGF-alpha)-mediated growth effects in ovarian cancer cell lines by a tyrosine kinase inhibitor ZM 252868. | Q36617561 | ||
| Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines | Q36821859 | ||
| Tyrosine kinase inhibition: an approach to drug development | Q40613606 | ||
| Transforming growth factor-alpha acts as an autocrine growth factor in ovarian carcinoma cell lines | Q41643277 | ||
| Mitogenic effects of epidermal growth factor and transforming growth factor-alpha on EGF-receptor positive human ovarian carcinoma cell lines | Q41645823 | ||
| Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts | Q42831208 | ||
| A specific inhibitor of the epidermal growth factor receptor tyrosine kinase | Q42834515 | ||
| Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. | Q43779560 | ||
| Estrogen regulation of transforming growth factor-alpha in ovarian cancer | Q48031429 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported | Q15643954 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| P304 | page(s) | 456-462 | |
| P577 | publication date | 2002-02-01 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 ("Iressa"). | |
| P478 | volume | 86 |
| Q38603140 | A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839) |
| Q37423291 | A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer |
| Q42963970 | A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149). |
| Q40364913 | A small molecule compound inhibits AKT pathway in ovarian cancer cell lines. |
| Q36981918 | Activated epidermal growth factor receptor in ovarian cancer. |
| Q55382724 | Anti-cancer effects of Kaempferia parviflora on ovarian cancer SKOV3 cells. |
| Q35548334 | Biologic directed therapies in gynecologic oncology |
| Q40234950 | Characterization of CSOC 882, a novel immortalized ovarian cancer cell line expressing EGFR, HER2, and activated AKT. |
| Q44541800 | Characterization of sequence-dependent synergy between ZD1839 ("Iressa") and oxaliplatin. |
| Q35053674 | Clinical proteomics: present and future prospects. |
| Q24626049 | Data-independent proteomic screen identifies novel tamoxifen agonist that mediates drug resistance |
| Q34525925 | Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors |
| Q26863231 | EGFR/HER-targeted therapeutics in ovarian cancer |
| Q28482093 | Efficacy of a non-hypercalcemic vitamin-D2 derived anti-cancer agent (MT19c) and inhibition of fatty acid synthesis in an ovarian cancer xenograft model |
| Q33642087 | Epidermal growth factor-induced GnRH-II synthesis contributes to ovarian cancer cell invasion |
| Q39884252 | F84, a quinazoline derivative, exhibits high potent antitumor activity against human gynecologic malignancies |
| Q35213252 | Future directions in the management of ovarian cancer |
| Q38798293 | Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2. |
| Q36790475 | Gonadotropins activate oncogenic pathways to enhance proliferation in normal mouse ovarian surface epithelium. |
| Q36695270 | Id-I stimulates cell proliferation through activation of EGFR in ovarian cancer cells |
| Q39990587 | Implications of EGFR inhibition in ovarian cancer cell proliferation |
| Q40619039 | Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level |
| Q36736349 | Investigational agents against platinum-resistant ovarian cancer |
| Q35968752 | Novel agents in epithelial ovarian cancer |
| Q36904860 | Novel agents in ovarian cancer. |
| Q35213223 | Oncogenic pathways implicated in ovarian epithelial cancer |
| Q36524232 | Photodynamic therapy activated signaling from epidermal growth factor receptor and STAT3: Targeting survival pathways to increase PDT efficacy in ovarian and lung cancer |
| Q30402667 | Proteomics and biomarkers in clinical trials for drug development |
| Q39998587 | Pyk2/ERK 1/2 mediate Sp1- and c-Myc-dependent induction of telomerase activity by epidermal growth factor |
| Q43005223 | Regulation of epidermal growth factor receptor in human colon cancer cell lines by interferon alpha |
| Q37034341 | Significant increase in hEGF uptake is correlated with formation of EGFR dimers induced by the EGFR tyrosine kinase inhibitor gefitinib |
| Q37485865 | Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. |
| Q36974713 | Thyrostimulin-TSHR signaling promotes the proliferation of NIH:OVCAR-3 ovarian cancer cells via trans-regulation of the EGFR pathway |
Search more.